ATE433115T1 - Timp-2 als ziel/marker des versagens von beta- zellen - Google Patents
Timp-2 als ziel/marker des versagens von beta- zellenInfo
- Publication number
- ATE433115T1 ATE433115T1 AT05760716T AT05760716T ATE433115T1 AT E433115 T1 ATE433115 T1 AT E433115T1 AT 05760716 T AT05760716 T AT 05760716T AT 05760716 T AT05760716 T AT 05760716T AT E433115 T1 ATE433115 T1 AT E433115T1
- Authority
- AT
- Austria
- Prior art keywords
- timp
- marker
- target
- cell failure
- beta cell
- Prior art date
Links
- 102000005354 Tissue Inhibitor of Metalloproteinase-2 Human genes 0.000 title abstract 2
- 108010031372 Tissue Inhibitor of Metalloproteinase-2 Proteins 0.000 title abstract 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 title abstract 2
- 239000003550 marker Substances 0.000 title 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 2
- 206010061818 Disease progression Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 230000005750 disease progression Effects 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/81—Protease inhibitors
- G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- G01N2333/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04103608 | 2004-07-28 | ||
| PCT/EP2005/007853 WO2006010529A1 (en) | 2004-07-28 | 2005-07-19 | Timp-2 as target/marker of beta cell failure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE433115T1 true ATE433115T1 (de) | 2009-06-15 |
Family
ID=34972635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05760716T ATE433115T1 (de) | 2004-07-28 | 2005-07-19 | Timp-2 als ziel/marker des versagens von beta- zellen |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20100009462A1 (de) |
| EP (1) | EP1774338B1 (de) |
| JP (1) | JP4562771B2 (de) |
| CN (1) | CN1993619A (de) |
| AT (1) | ATE433115T1 (de) |
| CA (1) | CA2574417C (de) |
| DE (1) | DE602005014778D1 (de) |
| ES (1) | ES2325789T3 (de) |
| WO (1) | WO2006010529A1 (de) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX342967B (es) | 2009-12-20 | 2016-10-19 | Astute Medical Inc | Metodos y composiciones para la diagnosis y prognosis de lesion renal y falla renal. |
| EP3540440B1 (de) | 2011-12-08 | 2022-09-28 | Astute Medical, Inc. | Verfahren und verwendungen zur bewertung von nierenschäden und nierenstatus |
| JP6681195B2 (ja) | 2013-01-17 | 2020-04-15 | アスチュート メディカル，インコーポレイテッド | 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物 |
| KR20160039682A (ko) | 2013-08-07 | 2016-04-11 | 아스튜트 메디컬 인코포레이티드 | 생물학적 샘플에서 개선된 성능을 가지는 timp2에 대한 검정 |
| CN110007084B (zh) | 2013-12-03 | 2022-11-18 | 阿斯图特医药公司 | 用于肾损伤和肾衰竭的诊断和预后的方法和组合物 |
| WO2016164854A1 (en) | 2015-04-09 | 2016-10-13 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| AU2017277305A1 (en) | 2016-06-06 | 2018-12-20 | Astute Medical, Inc. | Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2 |
| US10224053B2 (en) * | 2017-03-24 | 2019-03-05 | Hyundai Motor Company | Audio signal quality enhancement based on quantitative SNR analysis and adaptive Wiener filtering |
| WO2018187453A1 (en) * | 2017-04-05 | 2018-10-11 | Astute Medical, Inc. | Assays for timp2 having improved performance in biological samples |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1181939B1 (de) * | 1999-05-24 | 2006-05-31 | Shionogi & Co., Ltd. | Methode zum auswerten der in vivo matrix-metalloproteinasen hemmenden aktivität |
| US6673623B1 (en) * | 2000-09-12 | 2004-01-06 | Novocure, Inc. | Methods and compositions that control lipid production |
| AUPS282002A0 (en) * | 2002-06-06 | 2002-06-27 | Gropep Limited | Metalloproteinase inhibitors |
-
2005
- 2005-07-19 EP EP05760716A patent/EP1774338B1/de not_active Expired - Lifetime
- 2005-07-19 DE DE602005014778T patent/DE602005014778D1/de not_active Expired - Lifetime
- 2005-07-19 WO PCT/EP2005/007853 patent/WO2006010529A1/en not_active Ceased
- 2005-07-19 JP JP2007522979A patent/JP4562771B2/ja not_active Expired - Fee Related
- 2005-07-19 CA CA2574417A patent/CA2574417C/en not_active Expired - Fee Related
- 2005-07-19 US US11/658,517 patent/US20100009462A1/en not_active Abandoned
- 2005-07-19 AT AT05760716T patent/ATE433115T1/de not_active IP Right Cessation
- 2005-07-19 CN CNA2005800256144A patent/CN1993619A/zh active Pending
- 2005-07-19 ES ES05760716T patent/ES2325789T3/es not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1993619A (zh) | 2007-07-04 |
| JP2008508502A (ja) | 2008-03-21 |
| CA2574417C (en) | 2010-09-28 |
| JP4562771B2 (ja) | 2010-10-13 |
| EP1774338A1 (de) | 2007-04-18 |
| EP1774338B1 (de) | 2009-06-03 |
| CA2574417A1 (en) | 2006-02-02 |
| WO2006010529A1 (en) | 2006-02-02 |
| ES2325789T3 (es) | 2009-09-17 |
| US20100009462A1 (en) | 2010-01-14 |
| DE602005014778D1 (de) | 2009-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE528300T1 (de) | Bizyklische verbindungen und ihre verwendung als antidiabetika | |
| WO2006084195A3 (en) | Personal assessment including familial risk analysis for personalized disease prevention plan | |
| EA200971079A1 (ru) | ГЕНЕТИЧЕСКИЕ ВАРИАНТЫ В Chr5p12 И 10q26 В КАЧЕСТВЕ МАРКЕРОВ ДЛЯ ПРИМЕНЕНИЯ ПРИ ОЦЕНКЕ РИСКА, ДИАГНОСТИРОВАНИИ, ПРОГНОЗИРОВАНИИ И ЛЕЧЕНИИ РАКА ГРУДИ | |
| WO2009059150A3 (en) | Biomarkers for fatty liver disease and methods using the same | |
| EP1547996A4 (de) | Diagnostische sonden und heilmittel für krankheiten, bei denen prionprotein akkumuliert wird, und anfürbereagenzien für prionprotein | |
| ES2572372T3 (es) | Método de diagnóstico de enfermedades neurodegenerativas basado en la medición de los niveles o de la actividad de SIRT1 | |
| DE602006011896D1 (de) | Diagnoseverfahren für erkrankungen im zusammenhang mit hirnschäden | |
| ATE535612T1 (de) | Toxizitätsscreeningverfahren | |
| EA200800087A1 (ru) | Генетические варианты гена tcf7l2 как диагностические маркеры риска возникновения сахарного диабета ii типа | |
| DK2005162T3 (da) | Screeningsmetode | |
| WO2008122670A3 (en) | Human diabetes susceptibility tnfrsf10b gene | |
| WO2007134028A3 (en) | Biomarkers for depression and methods using the same | |
| WO2009019370A3 (fr) | Procede de dosage de l'apolipoproteine aii pour le diagnostic in vitro du cancer colorectal | |
| DE602005014778D1 (de) | Timp-2 als ziel/marker des versagens von beta-zellen | |
| WO2011143575A3 (en) | smFRET WITH MEMBRANE PROTEINS | |
| WO2006133287A3 (en) | Expression profiles of peripheral blood mononuclear cells for inflammatory bowel diseases | |
| MX339765B (es) | Metodos y composiciones para diagnostico y pronostico de lesion renal y falla renal. | |
| ATE468535T1 (de) | Verwendung von nnmt als marker für lungenkrebs | |
| WO2005034737A3 (en) | Methods for diagnosing and treating endoplasmic reticulum (er) stress diseases | |
| WO2006059252A3 (en) | Methods and fluorinated compositions for treating amyloid-related diseases | |
| WO2006092729A3 (en) | Novel biomarkers for diagnosis and/or prognosis or prognosis of neoplasias in animals | |
| DE602008004556D1 (de) | Zusammensetzungen und verfahren zum nachweis von störungen in verbindung mit histamin | |
| WO2006010533A3 (en) | Pancreatic polypeptide as target/marker of beta cell failure | |
| DE602005010712D1 (de) | Insulinpromotor-faktor 1 als target/marker von beta-zellen-störung | |
| FR2930036B1 (fr) | Procede de diagnostic d'une hypertension arterielle pulmonaire. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |